期刊文献+

基于神经血管单元和网络药理学理论的抗脑卒中神经病变靶点分析 被引量:16

Study about target-network of anti-cerebral infarction neuropathy based on theory of neurovascular unit and network pharmacology
原文传递
导出
摘要 目的:总结抗脑卒中神经病变的潜在药物靶点,为开发治疗脑卒中神经病变的创新组分中药提供资料。方法:根据国内外文献总结了脑缺血再灌注损伤导致神经血管单元的3种细胞即神经元、神经胶质细胞和脑微血管内皮细胞死亡和凋亡的信号机制。结果:重要通路有5个:炎性因子-MMPs通路-Caspases,Ca2+-线粒体通路-Caspases,Ca2+-磷脂酶-PI-3K/AK通路,Ca2+-自由基-MAPK通路,Ca2+-NO-蛋白酶通路。其中重要节点是Caspases,Ca2+和NO。结论:针对脑卒中神经病变信号网络的关键环节,发挥中药多层次多机制的特色,在神经血管单元和网络药理学理论指导下的创新组分中药开发极具价值。 Objective:Potention drug-targets on anti-neuropathy of stroke were summarized,and it will provide materials for developing innovation components traditional Chinese medicine on anti-cerebral infarction neuropathy.Method:This article had done a series of researching work about neurovascular unit which includes three kinds of cells:neuron,gliacyte,brain microvascular endothelial cell,then signal mechanism of cell death or apoptosis of each section of stroke neuropathy was analysised by the historical documents.Result:There are five important pathways:inflammatory factor-MMPs pathway-Caspases,Ca2+-mitochondrial pathway-Caspases,Ca2+-Phospholipase-PI-3K/AK pathway,Ca2+-radical-MAPK pathway,Ca2+-NO-protease pathway,among all the nodes,Caspases,Ca2+,No were the most important ones.Conclusion:Developing the multi-mechanism and multilevel of traditional chinese medicine under the guidance of the theories of network pharmacology and neurovascular unit will play an important role in studying the key links of signal-network of stroke neuropathy.
出处 《中国中药杂志》 CAS CSCD 北大核心 2012年第2期138-141,共4页 China Journal of Chinese Materia Medica
基金 国家自然科学基金面上项目(30973959 81173657)
关键词 脑卒中 神经病变 神经血管单元 网络药理学 创新组分中药 stroke neuropathy neurovascular unit network pharmacology innovation components Chinese medicine
  • 相关文献

参考文献3

二级参考文献80

  • 1王月华,杜冠华.复方小续命汤抗AD有效成分组研究[J].中成药,2005,27(9):993-996. 被引量:27
  • 2Feigin VL,Lawes CM,Bennett DA,et al.Worldwide stroke incidence and early case fatality reported in 56 population-based studies:a systematic review[J].Lancet Neurol,2009,8:355-869.
  • 3Johnston SC,Mendis S,Mathers CD.Global variation in stroke burden and mortality:estimates from monitoring,surveillance,and modeliing[J].Lancet Neurol,2009,8:345-354.
  • 4Amarenco P,Bogousslavsky J,Caplan LR,et al.Classification of stroke subtypes[J].Cerebrovasc Dis,2009,27:493-501.
  • 5Debette S,Seshadri S.Genetics of atherothrombotic and lacunar stroke[J].Circulation:Cardiovascular Genetics,2009,2:191-198.
  • 6Ikram MA,Seshadri S,Bis JC,et al.Genomewide association studies of stroke[J].N Engl J Med,2009,360:1718-1728.
  • 7Hara K,Shiga A,Fukutake T,et al.Association of HTRA1 mutations and familial ischemic cerebral small-vessel disease[J].N Engl J Med,2009,360:1729-1739.
  • 8Simon T,Verstuyft C,Pharm D,et al.Genetic determinants of response to clopidogrel and cardiovascular events[J].N Engl J Med 2009,360:363-375.
  • 9Mega JL,Close SL,Wiviott SD,et al.Cytochrome P-450 polymorphisms and response to clopidogre[J].N Engl J Med 2009;360:354-362.
  • 10Bluhmki E,Chamorro A,Dávalos A,et al.Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS Ⅲ):additional outcomes and subgroup analysis of a randomised controlled trial[J].Lancet Neurol,2009,8:1095-1102.

共引文献138

同被引文献186

引证文献16

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部